Endothelial tissue injury significantly contributes to ARDS in COVID-19 patients, finds study

A recent study conducted by scientists from the Yokohama City University, Japan, has revealed that elevated alveolar endothelial injury markers in coronavirus disease 2019 (COVID-19) patients with acute respiratory distress syndrome (ARDS) are the main causative factors for alveolar barrier disruption. In COVID-19 patients with ARDS, endothelial injury persists for a longer time than epithelial injury. The study is currently available on the medRxiv* preprint server.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Background

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has put a lot of burden on the healthcare and socioeconomic structures of many countries worldwide. Although a significant portion of COVID-19 patients remain asymptomatic or mildly symptomatic, the disease can contribute to serious complications in susceptible individuals. In its severe form, COVID-19 has been found to associate with ARDS. The presence of severe lung edema, together with alveolar epithelial and endothelial injuries, is the primary pulmonary characteristics of COVID-19 patients with ARDS. To develop effective therapeutic interventions, it is important to understand how alveolar tissue injury markers contribute to the pathogenesis of ARDS associated with COVID-19.    

Current study design

The scientists have enrolled COVID-19 patients with or without ARDS for this study. They have used serum samples obtained from these patients to measure the levels of alveolar epithelial and endothelial injury markers, namely soluble receptor for advanced glycation end-products (sRAGE) and angiopoietin-2 (ANG-2), respectively. In addition, the serum level of surfactant protein D (SP-D), which is a marker of alveolar barrier permeability, was measured.

In addition to comparing the levels of these markers between COVID-19 patients with or without ARDS, the scientists analyzed how the levels vary with time.  

Important observations

Of 9 COVID-19 patients with ARDS, 3 died during the study period; whereas all COVID-19 patients without ARDS (a total of 8 patients) survived. The clinical characteristics of ARDS patients have shown that the lungs are the primary organ to be affected by the disease. Of all ARDS COVID-19 patients, only one has developed acute kidney disease.

The biochemical analysis data reveal elevated serum levels of all alveolar tissue injury markers at the initial phase in both ARDS and non-ARDS COVID-19 patients. In COVID-19 patients with ARDS, a surge in the level of epithelial injury marker has been observed just after hospital admission; whereas, the peak levels of endothelial injury marker and alveolar barrier permeability marker have been observed during the later phase of the disease. These findings indicate that while alveolar epithelial injury occurs at the initial phase of the disease, endothelial injury continues for a longer time.

With further analysis, the scientists have observed that the circulating level of endothelial injury marker positively correlates with the level of alveolar barrier permeability marker and negatively correlates with the ratio of arterial oxygen partial pressure and fraction of inspired oxygen. However, an inverse correlation has been observed between epithelial injury marker and alveolar barrier permeability marker.

Temporal changes of (A) sRAGE, (B) ANG-2, and (C) SP-D levels in ARDS patients with COVID-19 for 14 days starting from admission. (D) The peak day of each of the alveolar tissue injury markers. Data were presented as median ± IQR.
Temporal changes of (A) sRAGE, (B) ANG-2, and (C) SP-D levels in ARDS patients with COVID-19 for 14 days starting from admission. (D) The peak day of each of the alveolar tissue injury markers. Data were presented as median ± IQR.

Study significance

Taken together, the study indicates that alveolar barrier tissue injury is one of the major features of ARDS associated with COVID-19. In COVID-19 patients with ARDS, damage to the alveolar epithelial tissue peaks at an early stage even before the hospital admission. In contrast, alveolar endothelial injury peaks at later stages of the disease and persists for several days after hospital admission.

Another important observation made in this study is that endothelial tissue injury is the main causative factor for alveolar permeability disruption in COVID-19 patients with ARDS. The scientists believe that SARS-CoV-2-mediated endothelial injury might be responsible for lung vascular thrombosis observed in COVID-19 patients.

Based on the overall study findings, the scientists suggest that therapeutic alleviation of endothelial injury rather than epithelial injury might be more effective in treating COVID-19 patients who also suffer with ARDS.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • Apr 3 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Dr. Sanchari Sinha Dutta

Written by

Dr. Sanchari Sinha Dutta

Dr. Sanchari Sinha Dutta is a science communicator who believes in spreading the power of science in every corner of the world. She has a Bachelor of Science (B.Sc.) degree and a Master's of Science (M.Sc.) in biology and human physiology. Following her Master's degree, Sanchari went on to study a Ph.D. in human physiology. She has authored more than 10 original research articles, all of which have been published in world renowned international journals.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dutta, Sanchari Sinha Dutta. (2023, April 03). Endothelial tissue injury significantly contributes to ARDS in COVID-19 patients, finds study. News-Medical. Retrieved on November 24, 2024 from https://www.news-medical.net/news/20210112/Endothelial-tissue-injury-significantly-contributes-to-acute-respiratory-distress-syndrome-(ARDS)-in-COVID-19-patients-finds-study.aspx.

  • MLA

    Dutta, Sanchari Sinha Dutta. "Endothelial tissue injury significantly contributes to ARDS in COVID-19 patients, finds study". News-Medical. 24 November 2024. <https://www.news-medical.net/news/20210112/Endothelial-tissue-injury-significantly-contributes-to-acute-respiratory-distress-syndrome-(ARDS)-in-COVID-19-patients-finds-study.aspx>.

  • Chicago

    Dutta, Sanchari Sinha Dutta. "Endothelial tissue injury significantly contributes to ARDS in COVID-19 patients, finds study". News-Medical. https://www.news-medical.net/news/20210112/Endothelial-tissue-injury-significantly-contributes-to-acute-respiratory-distress-syndrome-(ARDS)-in-COVID-19-patients-finds-study.aspx. (accessed November 24, 2024).

  • Harvard

    Dutta, Sanchari Sinha Dutta. 2023. Endothelial tissue injury significantly contributes to ARDS in COVID-19 patients, finds study. News-Medical, viewed 24 November 2024, https://www.news-medical.net/news/20210112/Endothelial-tissue-injury-significantly-contributes-to-acute-respiratory-distress-syndrome-(ARDS)-in-COVID-19-patients-finds-study.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Inequities in COVID-19 vaccination coverage for older adults highlighted in global study